79 related articles for article (PubMed ID: 24527863)
1. Cumulative survival analysis of patients with spinal myxopapillary ependymomas in the first 2 decades of life.
Kukreja S; Ambekar S; Sin AH; Nanda A
J Neurosurg Pediatr; 2014 Apr; 13(4):400-7. PubMed ID: 24527863
[TBL] [Abstract][Full Text] [Related]
2. Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas.
Davison MA; Lilly DT; Patel AA; Kashkoush A; Chen X; Wei W; Benzel EC; Prayson RA; Chao S; Angelov L
J Neurooncol; 2024 May; 167(3):437-446. PubMed ID: 38438766
[TBL] [Abstract][Full Text] [Related]
3. Analyzing the role of adjuvant or salvage radiotherapy for spinal myxopapillary ependymomas.
Kotecha R; Tom MC; Naik M; Angelov L; Benzel EC; Reddy CA; Prayson RA; Kalfas I; Schlenk R; Krishnaney A; Steinmetz MP; Bingaman W; Suh JH; Chao ST
J Neurosurg Spine; 2020 May; 33(3):392-397. PubMed ID: 32357340
[TBL] [Abstract][Full Text] [Related]
4. Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy.
Chen WC; Magill ST; Wu A; Vasudevan HN; Morin O; Aghi MK; Theodosopoulos PV; Perry A; McDermott MW; Sneed PK; Braunstein SE; Raleigh DR
J Neurosurg; 2018 Apr; 130(2):443-450. PubMed ID: 29624151
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiotherapy versus observation after gross total resection of WHO grade II ependymoma: a systematic review and individual-participant data meta-analysis.
Zheng Y; Ong SH; Nga VDW; Vellayappan B
Chin Clin Oncol; 2024 Apr; 13(2):22. PubMed ID: 38644544
[TBL] [Abstract][Full Text] [Related]
6. Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.
Casey DL; Kushner BH; Cheung NK; Modak S; LaQuaglia MP; Wolden SL
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):393-400. PubMed ID: 27473818
[TBL] [Abstract][Full Text] [Related]
7. Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007.
Amirian ES; Armstrong TS; Aldape KD; Gilbert MR; Scheurer ME
Neuroepidemiology; 2012; 39(2):116-24. PubMed ID: 22846789
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive treatment of myxopapillary ependymoma.
Jahanbakhshi A; Najafi M; Jafari F; Moshtaghian M; Gomar M; Anbarlouei M; Naderi S
Oncol Rev; 2021 Feb; 15(1):518. PubMed ID: 33824699
[TBL] [Abstract][Full Text] [Related]
9. Outcome predictors in the management of spinal myxopapillary ependymoma: an integrative survival analysis.
Kukreja S; Ambekar S; Sharma M; Sin AH; Nanda A
World Neurosurg; 2015 May; 83(5):852-9. PubMed ID: 25108296
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and survival in low grade gliomas of the spinal cord: A population-based analysis from 2006 to 2012.
Diaz-Aguilar D; ReFaey K; Clifton W; Durcanova B; Chen SG; Deen HG; Bydon M; Trifiletti DM; Pichelmann MA; Quiñones-Hinojosa A
J Clin Neurosci; 2019 Mar; 61():14-21. PubMed ID: 30528541
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network.
Weber DC; Wang Y; Miller R; Villà S; Zaucha R; Pica A; Poortmans P; Anacak Y; Ozygit G; Baumert B; Haller G; Preusser M; Li J
Neuro Oncol; 2015 Apr; 17(4):588-95. PubMed ID: 25301811
[TBL] [Abstract][Full Text] [Related]
12. Surgical outcomes of pediatric spinal cord astrocytomas: systematic review and meta-analysis.
Azad TD; Pendharkar AV; Pan J; Huang Y; Li A; Esparza R; Mehta S; Connolly ID; Veeravagu A; Campen CJ; Cheshier SH; Edwards MSB; Fisher PG; Grant GA
J Neurosurg Pediatr; 2018 Oct; 22(4):404-410. PubMed ID: 30028275
[TBL] [Abstract][Full Text] [Related]
13. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2.
J Neurosurg Spine; 2017 Apr; 26(4):474-482. PubMed ID: 27982762
[TBL] [Abstract][Full Text] [Related]
14. Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature.
Pusat S; Erbaş YC; Göçmen S; Kocaoğlu M; Erdoğan E
World Neurosurg; 2019 Jan; 121():239-242. PubMed ID: 30321682
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.
Horbinski C; Berger T; Packer RJ; Wen PY
Nat Rev Neurol; 2022 Sep; 18(9):515-529. PubMed ID: 35729337
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Personalized Prognostic Prediction Model for Patients With Spinal Cord Astrocytoma.
Yang S; Yang X; Wang H; Gu Y; Feng J; Qin X; Feng C; Li Y; Liu L; Fan G; Liao X; He S
Front Med (Lausanne); 2021; 8():802471. PubMed ID: 35118095
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic myxopapillary ependymoma: A case report and review of literature.
Kanno H; Kanetsuna Y; Shinonaga M
World J Clin Oncol; 2021 Nov; 12(11):1072-1082. PubMed ID: 34909401
[TBL] [Abstract][Full Text] [Related]
18. National trends in management of adult myxopapillary ependymomas.
Scarpelli DB; Turina CB; Kelly PD; Khudanyan A; Jaboin JJ; McClelland S
J Clin Neurosci; 2020 Mar; 73():162-167. PubMed ID: 31987634
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features of anaplastic myxopapillary ependymomas.
Lee JC; Sharifai N; Dahiya S; Kleinschmidt-DeMasters BK; Rosenblum MK; Reis GF; Samuel D; Siongco AM; Santi M; Storm PB; Ferris SP; Bollen AW; Pekmezci M; Solomon DA; Tihan T; Perry A
Brain Pathol; 2019 Jan; 29(1):75-84. PubMed ID: 30417460
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
